The Firm is representing Capsugel Holdings US, Inc. (“Capsugel”) in its acquisition of Bend Research, Inc. (“Bend Research”) as a part of Capsugel’s Dosage Form Solutions business unit. The transaction is expected to close within the next 30 days. Financial terms of the transaction were not disclosed.
Bend Research is an industry leader in bioavailability enhancement, particularly through Spray-Dried Dispersion formulation technology, and has developed technologies designed to address formulation challenges for oral drug delivery. Bend Research is headquartered in Bend, OR, and has 250 employees.
Capsugel is a global leader in providing dosage forms and solutions for the health care industry. Headquartered in Morristown, NJ, Capsugel employs 2,900 people, has 12 manufacturing and R&D facilities across three continents and serves more than 4,000 customers in over 100 countries. Capsugel was acquired by KKR in a 2011 carve-out acquisition from Pfizer.
The Simpson Thacher team included Jakob Rendtorff and Megan Vasios (M&A), Sarah Naseman (Executive Compensation and Employee Benefits), Nancy Mehlman and Adam Wells (Tax), Marcela Robledo and Zara Ohiorhenuan (IP), Adeeb Fadil and Noreen Lavan (Environmental), Krista McManus (Real Estate) and Joe Tringali, Michael Naughton, Kenneth Ehrhard and Ellen Frye (Antitrust).